By Keith Goldberg

Law360, New York (February 03, 2012, 4:53 PM ET) -- A Pennsylvania federal judge on Wednesday granted preliminary approval for the settlement of multidistrict consumer fraud litigation claiming Impax Laboratories Inc.'s generic version of the antidepressant Wellbutrin XL was deceptively labeled and is less effective and more dangerous than the brand-name pill.

The settlement calls for Impax, which developed and manufactures Budeprion XL, and Teva Pharmaceuticals USA Inc., which distributes the drug, to take several injunctive measures consistent with federal regulations relating to the state-law claims asserted against the companies, which were consolidated into an MDL...